On Dec 01, Eli Lilly and Company (NYSE:LLY) and AstraZeneca announced enrollment of the first patient into Amaranth, a Phase 2/3 study of an oral beta secretase cleaving enzyme (BACE) inhibitor currently in development as a potential treatment for Alzheimer’s disease. Eli Lilly and Company (NYSE:LLY) belongs to Healthcare sector. Its net profit margin is 13.20% and weekly performance is 7.52%. On last trading day … Continue reading Stocks in Focus : Liberty Interactive Corp (NASDAQ:LVNTA)